

Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study

Aftab Alam, MBBS, MS, MBA¹; Sagar Munjal, MD¹; Michael Reed, PhD²; Ryan Bostic²; Dawn Buse, PhD³; Todd Schwedt, MD⁴; David Dodick, MD⁴; Richard Lipton, MD^{3,5,6}

¹Promius Pharma, a subsidiary of Dr. Reddy's Laboratories, Princeton, NJ; ²Vedanta Research, Chapel Hill, NC; ³Department of Neurology, Albert Einstein College of Medicine, Bronx, NY; ⁴Mayo Clinic, Phoenix, AZ; ⁵Montefiore Medical Center, Bronx, NY; ⁶Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY

This study was supported and funded by the Dr. Reddy's Laboratories group of companies, Princeton, NJ.

Aftab Alam, MBBS, MS, MBA – Employee of Dr. Reddy’s Laboratories and owns stock in the company.

Sagar Munjal, MD, MS – Employee of Dr. Reddy’s Laboratories and owns stock in the company.

Michael L. Reed, PhD – Employee of Vedanta Research, which has received support funded by Allergan, Inc., Colucid, Dr. Reddy’s Laboratories, Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil, via grants to the National Headache Foundation.

Ryan Bostic – Employee of Vedanta Research, which has received support funded by Allergan, Inc., Colucid, Dr. Reddy’s Laboratories, Endo Pharmaceuticals, GlaxoSmithKline, Merck & Co., Inc., NuPathe, Novartis, and Ortho-McNeil, via grants to the National Headache Foundation.

Dawn C. Buse, PhD – Received grant support and honoraria from Allergan, Avanir, Amgen/ Novartis, Biohaven, Eli Lilly, Promius Pharma and Teva. She is on the editorial boards of Current Pain and Headache Reports, the Journal of Headache and Pain, Pain Medicine News, and Pain Pathways magazine.

Todd J. Schwedt, MD – Consultant, Scientific Advisory Board, or Speaker: Allergan, Amgen, ATI, Avanir, Dr. Reddy’s Laboratories, Nocira, Novartis, and Teva. Editor: Headache, Pain Medicine, and Cephalalgia journals.

David W. Dodick, MD – Within the last 12 months, Dr. Dodick reports personal fees from Amgen, Alder, Allergan, Autonomic Technologies, Biohaven, Eli Lilly, eNeura, Foresight Capital, Neurolief, Zosano, WL Gore, Vedanta Associates, Promius Pharma, Nocira, Novartis, Electrocore, Teva, Ipsen, Impel, Satsuma, Charleston Laboratories, Theranica. Compensation for activities related to data safety monitoring committee from Axsome. Compensation related to CME content development: Healthlogix, Medicom Worldwide, Medlogix Communications, MedNet, Miller Medical Communications, PeerView Operation Services America, Web MD/Medscape, American Academy of Neurology, American Headache Society, PeerView Institute for Medical Education, Chameleon Communications, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket Medical Education, Global Scientific Communications, UpToDate, Meeting LogiX. Royalties from editorial or book publishing: Oxford University Press, Cambridge University Press, Wiley Blackwell, Sage, Wolters Kluwer Health. Consulting use agreement through employer: NeuroAssessment Systems, Myndshft. Hold equity in: Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien. Board of Directors position: King-Devick Technologies, Ontologics.

Richard B. Lipton, MD – Dr. Richard B. Lipton is the Edwin S. Lowe Professor of Neurology at the Albert Einstein College of Medicine in New York. He receives research support from the NIH: 2P01 AG003949 (Program Director), 5U10 NS077308 (PI), 1R01 AG042595 (Investigator), RO1 NS082432 (Investigator), K23 NS09610 (Mentor), K23AG049466 (Mentor). He also receives support from the Migraine Research Foundation and the National Headache Foundation. He serves on the editorial board of Neurology and as senior advisor to Headache. He has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics and Biohaven Holdings; serves as consultant, advisory board member, or has received honoraria from: American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Colucid, Dr. Reddy’s Laboratories, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, Vedanta. He receives royalties from Wolff’s Headache, 8th Edition, Oxford Press University, 2009, Wiley and Informa.

Triptan Use and Discontinuation in Persons with Migraine

➤ Background

- ❖ Triptans are indicated for the acute treatment of migraine and are available in oral, injectable, and nasal forms
- ❖ Patients try various forms of triptans in the course of their migraine journey
- ❖ Understanding reasons for discontinuing triptans can help identify acute treatment needs

➤ Objectives

1. Understand past and current usage patterns for triptan medications
2. Understand reasons for discontinuation for oral and non-oral triptans

➤ **Migraine in America Symptoms and Treatment (MAST) Study**

- ❖ Baseline web-based survey conducted between October 2016 – January 2017
- ❖ 18+ years old, recruited from a US nationwide online research panel


➤ **Stratified random sampling to obtain panel representative of US population**

- ❖ ICHD-3 beta diagnostic criteria for migraine

➤ **Included**

- ❖ ≥ 3 headache days in past 3 months and ≥ 1 headache day in past 30 days
- ❖ Using acute prescription migraine medications

MAST Study Sample Results



- Survey questionnaire designed to capture:
 - ❖ Past and current triptan use by form
 - ❖ Reasons for discontinuing triptan medications by form
- For discontinuation due to side effect(s) respondents were asked to identify SEs from a pre-coded list
 - ❖ “Other” responses were allowed and coded
- Descriptive results are provided for each route of administration, but the groups are not mutually exclusive

MAST Results: Sociodemographics

	Total Sample N = 15,133 (%)	Total Current Rx Med Users N = 4,701 (%)	Total Current Triptan Users N = 2,421 (%)
Gender			
Male	27.0	28.4	22.8
Female	73.0	71.6	77.2
Race			
Non-White	19	18.2	15.3
White	81	81.8	84.7
Household Income			
Less than \$25,000	11.9	10.7	8.8
\$25,000 to \$49,999	21.2	19.8	18.2
\$50,000 to \$74,999	21.3	20.1	20.7
\$75,000 to \$99,999	17.0	18.9	19.4
More than \$100,000	25.8	30.4	33
Monthly HA Days			
1 to 4	62.6	51.2	48.5
5 to 9	19.9	23.7	25
10 to 14	7.9	10.5	10.8
15+	9.6	14.6	15.7
Age Mean [SD]	43.11 [13.6]	44.78 [13.4]	45.07 [13.0]
BMI Mean [SD]	28.23 [7.6]	28.11 [7.8]	27.77 [7.5]
Monthly HA Days Mean [SD]	5.56 [6.0]	7.03 [6.9]	7.34 [7.1]

MAST Results: Past and Current Triptan Use by Form




	Oral	Injectable	Nasal Spray	Total
Triptan Use in MAST Sample (N=15,133)				
Current triptan users	2050 (13.5%)	197 (1.3%)	400 (2.6%)	2421 (15.9%)
Discontinued triptan users	2529 (16.7%)	867 (5.7%)	794 (5.2%)	3175 (21.0%)
Ever (past and current) triptan users	4579 (30.3%)	1064 (7.0%)	1194 (7.9%)	5596 (37.0%)
Triptan use among ever Triptan Users				
Current triptan users	2050 (44.8%)	197 (18.5%)	400 (33.5%)	2421 (43.3%)
Discontinued triptan users	2529 (55.2%)	867 (81.5%)	794 (66.5%)	3175 (56.7%)

Discontinuation rates were highest for injectable triptans (81.5%) followed by nasal sprays (66.5%) and oral (55.2%)


MAST Results: Current Triptan Use Overlap

	Oral (N = 2050)	Injectable (N = 197)	Nasal Spray (N = 400)
Oral	2050 (100%)	102 (51.8%)	111 (27.8%)
Injectable	102 (5.0%)	197 (100%)	28 (7.0%)
Nasal Spray	111 (5.4%)	28 (14.2%)	400 (100%)

MAST Results: Reasons for Discontinuation of Triptan Medications by Route of Administration (1 of 2)



MAST Results: Reasons for Discontinuation of Triptan Medications by Route of Administration (2 of 2)




^aSpecific mentions: Nasal drip, burning, congestion n=28(38.8%), Disliked smell/taste n=22(30.5%)


^bSpecific mentions: Dislike needles n=38 (52.8%), Pain n=19 (26.3%)

*Among Women only (Oral N=2086, Injectable N=589, Nasal Spray N=511)

MAST Results: Side Effects that Led to Discontinuation of Triptan Medications (1 of 2)



MAST Results: Side Effects that Led to Discontinuation of Triptan Medications (2 of 2)



- More than one third of study participants with migraine have ever used a triptan and 15.9% were current users of one or more routes of administration.
- While oral treatment is the most common, 11.5% have ever used a non-oral route of administration.
- Among ever triptan users, 56.7% have discontinued use indicating substantial unmet medical needs.

Thank You!



**Sagar Munjal,
MD, MS**



**Michael L. Reed,
PhD**



Ryan Bostic



**Dawn C. Buse,
PhD**

**Todd J. Schwedt,
MD**



**David W. Dodick,
MD**



**Richard B. Lipton,
MD**

